For instance, medications that help with the psychological effects of schizophrenia might also help with schizoid personality disorder. Stimulants, which are medications that energize people, and ...
The US Food and Drug Administration (FDA) has approved a drug for schizophrenia that is exciting the field with an entirely ...
The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...
While momentous, the approval of Cobenfy could also draw attention to an age-old problem in American healthcare: Will insurance barriers keep patients from getting an effective medicine?
Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel ...
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.
Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...
The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...
The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...
The U.S. Food and Drug Administration (FDA) on Thursday approved Cobenfy (xanomeline and trospium chloride), developed by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback